乌干达有症状COVID-19患者中COVID-19疫苗对SARS-CoV-2感染的有效性
调整后总体疫苗有效性为45%至59%,敏感性分析中降至32%至38%,提示末次接种后12个月内对症状性感染有中等保护。
要点
- 有症状感染者中,病例组全程接种97例(56%),对照组701例(59%),p=0.830。
- 总体调整疫苗有效性为45%至59%,在年度、绝对和相对三种评估方式中保持一致。
- 排除既往感染者后,敏感性分析显示疫苗有效性降低至32%至38%。
核心结论
- COVID-19疫苗接种对末次接种后12个月内的症状性SARS-CoV-2感染提供中等保护,强调高风险个体及时接种疫苗的重要性。
- 本研究及其他非洲环境中缺乏明确的COVID-19季节性,给选择年度疫苗接种的最佳时机带来挑战。
研究设计与样本
- 2023至2024年在乌干达19家医疗中心开展的检测阴性病例对照研究,纳入有COVID-19样症状的参与者。
- 病例为有咳嗽、咽痛、鼻溢等任意三种症状且PCR确诊SARS-CoV-2的患者,对照为SARS-CoV-2 PCR阴性者。
主要发现
- 病例组中全程接种97例(56%),对照组中全程接种701例(59%),p=0.830。
- 总体调整疫苗有效性为45%至59%,在年度、绝对和相对三种评估方式中保持一致。
- 敏感性分析排除既往SARS-CoV-2感染者后,所有评估方式中疫苗有效性均一致降低至32%至38%。
关键数值与推荐
- 疫苗有效性计算为1减去调整比值比,基于末次接种后天数分为三组:<365天、7-269天和270-364天。
- 调整因素包括年龄、性别、日历时间和慢性疾病。
- 年度评估:过去12个月内接种(无论剂次) vs 症状发作前超过12个月接种加未接种。
- 绝对评估:过去12个月内接种 vs 未接种。
- 相对评估:过去12个月内接种 vs 症状发作前超过12个月接种。
临床怎么用
- 作者认为COVID-19疫苗接种对末次接种后12个月内的症状性SARS-CoV-2感染提供中等保护。
- 作者强调高风险个体及时接种疫苗的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 vaccines significantly reduce severe disease outcomes, but uncertainty remains about long-term protection. We investigated vaccine effectiveness (VE) against SARS-CoV-2 infection over extended periods in the World Health Organisation AFRO-MoVE network studies in Africa. METHODS: Participants with COVID-19-like symptoms were recruited between 2023 and 2024 for a test-negative case-control study conducted across 19-healthcare centres in Uganda. Cases were symptomatic patients with any three of cough, sore-throat, coryza, among others, and PCR-confirmed SARS-CoV-2, while controls were SARS-CoV-2 PCR-negative. Vaccination was verified from vaccination cards, hospital-records, vaccination registry and self-reporting. VE was assessed through three measures: (a) Annual - patients vaccinated in the past 12-months regardless of dose vs those vaccinated >12-months before symptom onset plus unvaccinated; (b) Absolute - patients vaccinated in the past 12-months vs unvaccinated; and (c) Relative - patients vaccinated in the past 12-months vs those vaccinated >12-months before symptom onset. VE was calculated as 1- adjusted odds ratio for three patient groups based on days since the last dose; (1) <365, (2) 7-269 and (3) 270-364 while adjusting for age, sex, calendar-time and chronic conditions. The sensitivity analysis excluded patients that were previously infected with SARS-CoV-2. FINDINGS: In total, 1371 patients, 56 % female were recruited. Of these, 173 were classified as cases, with 97 (56 %) fully vaccinated compared to 701 (59 %) controls, p = 0.830. The overall adjusted VE was moderate, 45 % to 59 %, and remained consistent across the annual, absolute and relative measures. Sensitivity analysis showed consistently lower VE (32 % to 38 %) across all measures. INTERPRETATION: The results suggest that COVID-19 vaccination provides moderate protection against symptomatic SARS-CoV-2 infection up to 12-months after the last dose and highlight the importance of up-to-date vaccinations for high-risk individuals. The lack of clear COVID-19 seasonality in this and other African settings creates a challenge to selecting the optimal timing for annual vaccination.
引用
- Abaasa AM, Kusemererwa S, Ankunda V, et al. Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda. Vaccine. 2025. PMID: 40055029. doi:10.1016/j.vaccine.2025.126976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。